| ²é¿´: 339 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
| Contrary to preclinical experiments, where long-term benefit of VEGF (receptor) inhibition can be achieved, the clinical benefit in prolonging cancer patient survival with advanced disease is limited, and a fraction of patients are intrinsically refractory or acquire resistance . Recent trials using VEGF (receptor) blockers showed that the benefit, initially reported for progres-sion-free survival, was no longer detected when analyzing overall survival . |
» ²ÂÄãϲ»¶
281Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
»ªÄÏÀí¹¤0703»¯Ñ§£¬×Ü·Ö336Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
285Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ13È˻ظ´
295Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
²ÄÁÏÓ뻯¹¤×¨Ë¶306·ÖÕÒºÏÊʵ÷¼Á
ÒѾÓÐ3È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ11È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ21È˻ظ´
²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
319Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´

nwsuafliu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 144
- Ó¦Öú: 42 (СѧÉú)
- ½ð±Ò: 2406.9
- É¢½ð: 1449
- ºì»¨: 18
- Ìû×Ó: 1437
- ÔÚÏß: 315.6Сʱ
- ³æºÅ: 136928
- ×¢²á: 2005-12-17
- רҵ: ×÷Îï·Ö×ÓÓýÖÖ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-01-30 16:47:03
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-01-30 16:47:03
| ÁÙ´²Ç°ÊÔÑéÖÐÒÖÖÆÑª¹ÜÄÚÆ¤Éú³¤Òò×Ó(ÊÜÌå)¿ÉÒÔʵÏÖ³¤ÆÚ¸ÄÉÆ£¬ÓëÖ®Ïà·´£¬ÁÙ´²ÉÏÑÓ³¤ÍíÆÚ°©Ö¢²¡ÈË´æ»îÂʵÄЧ¹ûÓÐÏÞ£¬²¿·Ö²¡È˱¾ÖÊÉÏÄÑÒÔÖÎÓú»òÕß»ñµÃ¿¹ÐÔ¡£½üÀ´ÀûÓÃѪ¹ÜÄÚÆ¤Éú³¤Òò×Ó(ÊÜÌå)×è¶Ï¼ÁµÄÊÔÑé±íÃ÷£¬µ±¶Ô×ÜÉú´æÆÚ½øÐзÖÎöʱ£¬²¢Î´·¢ÏÖ×î³õ±¨µÀµÄÎÞ¶ñ»¯Éú´æÆÚ¸ÄÉÆ¡£ |

2Â¥2013-01-27 17:28:52














»Ø¸´´ËÂ¥